Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| SA-220641k | SA-220641k | U.S. | 1997 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | D4T | 22 |
| 2 | D4T+SQV | 21 |
| 3 | 3TC+D4T+SQV | 41 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| G48V, I54V, L90M | L10I, G16E, P39T, L63P, A71T, V77VI |
| >SA-220641k| codons 1-99 PQITLWQRPIVTIKIEGQLKEALLDTGADDTVLEEMNLTGRWKPKMIVGIGGFVKVRQYD QIPIEICGHKTIGTVLIGPTPVNIIGRNLMTQIGCTLNF |
References
| Author | Title | Citation |
| Sevin, AD | Methods for investigating the relationship between drug-susceptibility phenotype and HIV-1 genotype with applications to ACTG 333. | J Infect Dis, 2000 |
| Wu, TD | Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. | J Virol, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |